Related Experiment Video
Updated: Jul 2, 2026

Enhancing the Development and Growth of Infant Cerebral Palsy Rats Using Selective Spinal Manipulations
Published on: February 2, 2024
[Botulinum toxin in infantile cerebral palsy]
P Póo1, M Galván-Manso, M J Casartelli
1Servicio de Neuropediatría, Unidad Integrada Hospital Sant Joan de Déu-Clínic, E-08950 Esplugues de Llobregat, Barcelona. pilarpoo@hsjdbnc.org
Introduction:
A number of studies have proved the effectiveness and safety of botulinum toxin in therapeutic doses.
Aim:
To analyse the results obtained over a 12-year period in which botulinum toxin type A (BTA) was used to treat infantile cerebral palsy (CP).
Patients And Methods:
Of a total number of 547 patients who were treated, 515 had CP, 464 with spasticity, 46 with mixed CP and 5 with dyskinetic CP with focal dystonia.
Results:
Overall evaluation of BTA is positive, both as regards its beneficial effects and its safety: tone was mildly improved in 18.5% of patients, with no change in motor functioning, 39% showed a moderate improvement, 19% a marked improvement and 5.6% experienced a marked and prolonged improvement. Forty-two patients (8.15%) presented side effects, the most common being weakness in the lower limbs, which occurred in 21 cases.
Conclusions:
BTA is a good therapeutic option for treating children with CP, not only for the focal involvement but also as palliative treatment in children with diffuse involvement.
Related Concept Videos
Botulism
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Tetanus
Skeletal Muscle Relaxants: Therapeutic Uses
Depolarizing Blockers: Pharmocokinetics
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...

